On July 29, local time, Johnson & Johnson announced the completion of the acquisition of biotechnology company Firefly Bio, with consideration of 1 billion US dollars in cash. Johnson & Johnson said the deal will be recorded as an asset acquisition and is expected to generate about 1 billion US dollars in R&D expenses in the third quarter of 2026. The company expects the transaction to dilute the 2026 adjusted operating earnings per share and adjusted earnings per share by approximately $0.46, and the 2027 dilution by approximately $0.08.

On July 29, local time, Johnson & Johnson announced the completion of the acquisition of biotechnology company Firefly Bio, with consideration of 1 billion US dollars in cash. Johnson & Johnson said the deal will be recorded as an asset acquisition and is expected to generate about 1 billion US dollars in R&D expenses in the third quarter of 2026. The company expects the transaction to dilute the 2026 adjusted operating earnings per share and adjusted earnings per share by approximately $0.46, and the 2027 dilution by approximately $0.08.